SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure
Item 7.01.>Regulation FD Disclosure.
SELECTA BIOSCIENCES, INC. (NASDAQ:SELB) Files An 8-K Regulation FD Disclosure
EX-99.1 2 selbcorporatepresentatio.htm EXHIBIT 99.1 selbcorporatepresentatio Corporate Presentation October 2019 SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations,…
To view the full exhibit click
here
About SELECTA BIOSCIENCES, INC. (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.